Cited by 344Prostate Cancer Treatment and ResearchHER2/EGFR in Cancer ResearchEstrogen and related hormone effects

The DOI matches its Crossref record; 75 of the 80 references it cites were found in a registry or an index.

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Open access

Mellinghoff, Ingo K., Vivanco, Igor, Kwon, Andrew, Tran, Chris, Wongvipat, John, Sawyers, Charles L.·2004·Cancer Cell

DOI 10.1016/j.ccr.2004.09.031

Open this paper in CoChat — free account

Abstract

Given the role of the EGFR/HER2 family of tyrosine kinases in breast cancer, we dissected the molecular basis of EGFR/HER2 kinase signaling in prostate cancer. Using the small molecule dual EGFR/HER2 inhibitor PKI-166, we show that the biologic effects of EGFR/HER-2 pathway inhibition are caused by reduced AR transcriptional activity. Additional genetic and pharmacologic experiments show that this modulation of AR function is mediated by the HER2/ERBB3 pathway, not by EGFR. This HER2/ERBB3 signal stabilizes AR protein levels and optimizes binding of AR to promoter/enhancer regions of androgen-regulated genes. Surprisingly, the downstream signaling pathway responsible for these effects appears to involve kinases other than Akt. These data suggest that the HER2/ERBB3 pathway is a critical target in hormone-refractory prostate cancer.

Integrity signals

Registry

Crossref · 10.1016/j.ccr.2004.09.031

Cites

75 of 75 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu Oncogene
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760
Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei
Dignam, J. D., Lebovitz, R. M., & Roeder, R. G. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.5.1475 · Cited by 11,262
Sequence and structure-based prediction of eukaryotic protein phosphorylation sites
Blom, N., Gammeltoft, S., & Brunak, S. (1999) · Journal of Molecular Biology · doi:10.1006/jmbi.1999.3310 · Cited by 3,212
The ErbB signaling network: receptor heterodimerization in development and cancer
Olayioye, M. A., Neve, R. M., Lane, H. A., & Hynes, N. E. (2000) · The EMBO Journal · doi:10.1093/emboj/19.13.3159 · Cited by 2,489
Molecular determinants of resistance to antiandrogen therapy
Chen, C. D., Welsbie, D. S., Tran, C., Baek, S. H., Chen, R., Vessella, R., Rosenfeld, M. G., & Sawyers, C. L. (2004) · Nature Medicine · doi:10.1038/nm972 · Cited by 2,278
Self-citation
Activation of the estrogen receptor through phosphorylation by mitogen-activated protein kinase
Kato, S., Endoh, H., Masuhiro, Y., Kitamoto, T., Uchiyama, S., Sasaki, H., Masushige, S., Gotoh, Y., Nishida, E., Kawashima, H., et al. (1995) · Science · doi:10.1126/science.270.5241.1491 · Cited by 1,964
Phosphorylation-induced binding and transcriptional efficacy of nuclear factor CREB
Yamamoto, K. K., Gonzalez, G. A., Biggs, W., & Montminy, M. (1988) · Nature · doi:10.1038/334494a0 · Cited by 1,281
A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase
Craft, N., Shostak, Y., Carey, M., & Sawyers, C. L. (1999) · Nature Medicine · doi:10.1038/6495 · Cited by 980
The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation
Holbro, T., Beerli, R. R., Maurer, F., Koziczak, M., Barbas, C. F., & Hynes, N. E. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1537685100 · Cited by 952
Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor.
Čulig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., Bartsch, G., & Klocker, H. (1994) · PubMed · Cited by 938

Show all 80 references

Sorted by citations

Reciprocal Feedback Regulation of PI3K and Androgen Receptor Signaling in PTEN-Deficient Prostate Cancer
Carver, B. S., Chapinski, C., Wongvipat, J., Hieronymus, H., Chen, Y., Chandarlapaty, S., Arora, V. K., Le, C. H., Koutcher, J. A., Scher, H. I., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.04.008 · Cited by 1,227
Novel anticancer targets: revisiting ERBB2 and discovering ERBB3
Baselga, J. M., & Swain, S. M. (2009) · Nature reviews. Cancer · doi:10.1038/nrc2656 · Cited by 1,170
Biology of Progressive, Castration-Resistant Prostate Cancer: Directed Therapies Targeting the Androgen-Receptor Signaling Axis
Scher, H. I., & Sawyers, C. L. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.4777 · Cited by 1,025
Self-citation
Androgen receptor: structure, role in prostate cancer and drug discovery
Tan, M.-H., Li, J., Xu, H. E., Melcher, K., & Yong, E. (2014) · Acta Pharmacologica Sinica · doi:10.1038/aps.2014.18 · Cited by 1,000
Molecular genetics of prostate cancer: new prospects for old challengesPreprint
Shen, M. M., & Abate-Shen, C. T. (2010) · Genes & Development · doi:10.1101/gad.1965810 · Cited by 991
Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches
Karantanos, T., Corn, P. G., & Thompson, T. C. (2013) · Oncogene · doi:10.1038/onc.2013.206 · Cited by 894
Identification of molecular apocrine breast tumours by microarray analysis
Farmer, P. J., Bonnefoi, H. R., Becette, V., Tubiana-Hulin, M., Fumoleau, P., Larsimont, D., MacGrogan, G. M., Bergh, J. C. S., Cameron, D., Goldstein, D., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208561 · Cited by 822
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 652
An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen
Doane, A. S., Danso, M. A., Lal, P., Donaton, M., Zhang, L., Hudis, C. A., & Gerald, W. L. (2006) · Oncogene · doi:10.1038/sj.onc.1209415 · Cited by 613
The role of HER2 in cancer therapy and targeted drug delivery
Tai, W., Mahato, R., & Cheng, K. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.04.009 · Cited by 557
Cutaneous side-effects of kinase inhibitors and blocking antibodies
Robert, C., Soria, J., Spatz, A., Cesne, A. L., Malka, D., Pautier, P., Wechsler, J., Lhommé, C., Escudier, B. J., Boige, V., et al. (2005) · The Lancet Oncology · doi:10.1016/s1470-2045(05)70243-6 · Cited by 551
Androgen receptors in hormone-dependent and castration-resistant prostate cancer
Shafi, A. A., Yen, A. E., & Weigel, N. L. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.003 · Cited by 435
Androgen Signaling in Prostate CancerPreprint
Dai, C. S., Heemers, H. V., & Sharifi, N. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a030452 · Cited by 432
Targeting Androgen Receptor in Estrogen Receptor-Negative Breast Cancer
Ni, M., Chen, Y., Lim, E., Wimberly, H., Bailey, S. T., Imai, Y., Rimm, D. L., Liu, X. S., & Brown, M. A. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.05.026 · Cited by 401
Targeting the androgen receptor pathway in prostate cancer
Chen, Y., Sawyers, C. L., & Scher, H. I. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2008.07.005 · Cited by 393
Targeting the PI3K/AKT Pathway for the Treatment of Prostate Cancer
Sarker, D., Reid, A. H. M., Yap, T. A., & de Bono, J. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0125 · Cited by 366
Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target
Chen, Y., Clegg, N. J., & Scher, H. I. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70229-3 · Cited by 322
Targeting the PI3K/Akt/mTOR pathway in castration-resistant prostate cancer
Bitting, R. L., & Armstrong, A. J. (2013) · Endocrine Related Cancer · doi:10.1530/erc-12-0394 · Cited by 316
Androgen receptor and growth factor signaling cross-talk in prostate cancer cells.
Zhu, M.-L., & Kyprianou, N. (2008) · Endocrine Related Cancer · doi:10.1677/erc-08-0084 · Cited by 286
Understanding the Mechanisms of Androgen Deprivation Resistance in Prostate Cancer at the Molecular Level
Karantanos, T., Evans, C. P., TOMBAL, B. F., Thompson, T. C., Montironi, R., & Isaacs, W. B. (2014) · European Urology · doi:10.1016/j.eururo.2014.09.049 · Cited by 292
Activated Cdc42-associated kinase Ack1 promotes prostate cancer progression via androgen receptor tyrosine phosphorylation.
Mahajan, N. P., Liu, Y., Majumder, S., Warren, M. R., Parker, C. E., Mohler, J. L., Earp, H. S., & Whang, Y. E. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700420104 · Cited by 274
Tumor Microenvironment-Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer
Zhang, Z., Karthaus, W. R., Lee, Y. S., Gao, V. R., Wu, C., Russo, J. W., Liu, M., Mota, J. M., Abida, W. M., Linton, E. L., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.005 · Cited by 260
The ERBB3 receptor in cancer and cancer gene therapy
Sithanandam, G., & Anderson, L. M. (2008) · Cancer Gene Therapy · doi:10.1038/cgt.2008.15 · Cited by 240
Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells
Amicis, F. D., Janagi, T., Cui, Y., Selever, J., Beyer, A. R., Parra, I., Weigel, N. L., Herynk, M. H., Tsimelzon, A. I., Lewis, M. T., et al. (2009) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0436-8 · Cited by 229
Activated Tyrosine Kinase Ack1 Promotes Prostate Tumorigenesis: Role of Ack1 in Polyubiquitination of Tumor Suppressor Wwox
Mahajan, N. P., Whang, Y. E., Mohler, J. L., & Earp, H. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1127 · Cited by 228
Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer
Galletti, G., Leach, B. I., Lam, L., & Tagawa, S. T. (2017) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.04.008 · Cited by 219
Bisphenol A affects androgen receptor function via multiple mechanisms
Teng, C. T., Goodwin, B. L., Shockley, K. R., Xia, M., Huang, R., Norris, J. D., Merrick, B. A., Jetten, A. M., Austin, C. P., & Tice, R. R. (2013) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2013.03.013 · Cited by 211
Mechanisms mediating androgen receptor reactivation after castration
Yuan, X., & Balk, S. P. (2008) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2008.03.021 · Cited by 207
Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1
Chen, S., Xu, Y., Yuan, X., Bubley, G. J., & Balk, S. P. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604193103 · Cited by 202
Steroid Receptor Phosphorylation: A Key Modulator of Multiple Receptor Functions
Weigel, N. L., & Moore, N. L. T. (2007) · Molecular Endocrinology · doi:10.1210/me.2007-0101 · Cited by 196
Rapid Induction of Androgen Receptor Splice Variants by Androgen Deprivation in Prostate Cancer
Yu, Z., Chen, S., Sowalsky, A. G., Voznesensky, O. S., Mostaghel, E. A., Nelson, P. S., Cai, C., & Balk, S. P. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1863 · Cited by 198
Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
Gan, L., Chen, S., Wang, Y., Watahiki, A., Bohrer, L. R., Sun, Z. K., Wang, Y. Z., & Huang, H. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1504 · Cited by 199
Differential Expression of Hormonal and Growth Factor Receptors in Salivary Duct Carcinomas
Williams, M. D., Roberts, D. B., Blumenschein, G. R., Temam, S., Kies, M. S., Rosenthal, D. I., Weber, R. S., & El‐Naggar, A. K. (2007) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e3180caa099 · Cited by 191
Suppression of androgen receptor-mediated gene expression by a sequence-specific DNA-binding polyamide
Nickols, N. G., & Dervan, P. B. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704217104 · Cited by 189
Androgen action and metabolism in prostate cancer
Green, S. M., Mostaghel, E. A., & Nelson, P. S. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.09.046 · Cited by 191
Interleukin-6: A multifunctional targetable cytokine in human prostate cancer
Čulig, Z., & Puhr, M. (2011) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.05.033 · Cited by 179
Metastatic prostate cancer remains incurable, why?
Dong, L., Zieren, R. C., Xue, W., de Reijke, T. M., & Pienta, K. J. (2018) · Asian journal of urology · doi:10.1016/j.ajur.2018.11.005 · Cited by 177
miR-331-3p Regulates ERBB-2 Expression and Androgen Receptor Signaling in Prostate Cancer
Epis, M. R., Giles, K. M., Barker, A. J., Kendrick, T. S., & Leedman, P. J. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.030098 · Cited by 164
AR Signaling and the PI3K Pathway in Prostate Cancer
Crumbaker, M., Khoja, L., & Joshua, A. M. (2017) · Cancers · doi:10.3390/cancers9040034 · Cited by 174
A Functionally Significant Cross-talk between Androgen Receptor and ErbB2 Pathways in Estrogen Receptor Negative Breast Cancer
Naderi, A., & Hughes‐Davies, L. (2008) · Neoplasia · doi:10.1593/neo.08274 · Cited by 162
ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli
Tapinos, N., Ohnishi, M., & Rambukkana, A. (2006) · Nature Medicine · doi:10.1038/nm1433 · Cited by 153
Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies
Mimeault, M., & Batra, S. K. (2005) · Carcinogenesis · doi:10.1093/carcin/bgi229 · Cited by 156
Molecular Mechanisms of ErbB2-Mediated Breast Cancer Chemoresistance
Tan, M., & Yu, D. (2007) · Advances in experimental medicine and biology · doi:10.1007/978-0-387-74039-3_9 · Cited by 151
Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer
Lamont, K. R., & Tindall, D. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0469 · Cited by 150
Regulation of Survivin by ErbB2 Signaling: Therapeutic Implications for ErbB2-Overexpressing Breast Cancers
Xia, W., Bisi, J., Strum, J. C., Liu, L.-H., Carrick, K., Graham, K. M., Treece, A. L., Hardwicke, M. A., Dush, M. K., Liao, Q., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2000 · Cited by 150
Involvement of arginine methyltransferase CARM1 in androgen receptor function and prostate cancer cell viability
Majumder, S., Liu, Y., Ford, O. H., Mohler, J. L., & Whang, Y. E. (2006) · The Prostate · doi:10.1002/pros.20438 · Cited by 146
Decreased Expression and Androgen Regulation of the Tumor Suppressor Gene INPP4B in Prostate Cancer
Hodgson, M. C., Shao, L.-J., Frolov, A., Li, R., Peterson, L. E., Ayala, G., Ittmann, M., Weigel, N. L., & Agoulnik, I. U. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2314 · Cited by 142
Androgen receptor action in hormone‐dependent and recurrent prostate cancer
Agoulnik, I. U., & Weigel, N. L. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20811 · Cited by 141
Combinatorial activities of Akt and B-Raf/Erk signaling in a mouse model of androgen-independent prostate cancer.
Gao, H., Ouyang, X., Banach-Petrosky, W. A., Gerald, W. L., Shen, M. M., & Abate-Shen, C. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606836103 · Cited by 141
Expression and Nuclear Localization of ErbB3 in Prostate Cancer
Koumakpayi, I. H., Diallo, J., Page, C. L., Lessard, L., Gleave, M. E., Bégin, L. R., Mes‐Masson, A., & Fred Saad, C. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2242 · Cited by 140
Hepatitis B virus X protein enhances androgen receptor-responsive gene expression depending on androgen level
Chiu, C.-M., Yeh, S., Chen, P., Kuo, T.-J., Chang, C.-J., Chen, P., Yang, W., & Chen, D. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609498104 · Cited by 135
Open-Label Phase II Study Evaluating the Efficacy and Safety of Two Doses of Pertuzumab in Castrate Chemotherapy-Naive Patients With Hormone-Refractory Prostate Cancer
Bono, J. S. D., Joaquim Bellmunt, B., Attard, G., Droz, J. P., Miller, K., Fléchon, A., Sternberg, C. N., Parker, C. C., Zugmaier, G., Hersberger-Gimenez, V., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0888 · Cited by 137
Apoptosis evasion: The role of survival pathways in prostate cancer progression and therapeutic resistance
McKenzie, S. P., & Kyprianou, N. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20634 · Cited by 130
Targeting the adaptive molecular landscape of castration‐resistant prostate cancer
Wyatt, A. W., & Gleave, M. E. (2015) · EMBO Molecular Medicine · doi:10.15252/emmm.201303701 · Cited by 130
Targeting ErbB2 and ErbB3 with a bispecific single-chain Fv enhances targeting selectivity and induces a therapeutic effect in vitro
Robinson, M. K., Hodge, K. M., Horak, E. M., Sundberg, Å. L., Russeva, M., Shaller, C. C., von Mehren, M., Shchaveleva, I., Simmons, H. H., Marks, J. D., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604700 · Cited by 131
CXCL12/CXCR4 Transactivates HER2 in Lipid Rafts of Prostate Cancer Cells and Promotes Growth of Metastatic Deposits in Bone
Chinni, S., Yamamoto, H., Dong, Z.-Y., Sabbota, A. L., Bonfil, R., & Cher, M. L. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0117 · Cited by 146
AR Signaling in Breast Cancer
Rahim, B. G., & O'Regan, R. M. (2017) · Cancers · doi:10.3390/cancers9030021 · Cited by 122
Signal transduction in prostate cancer progression
Gioeli, D. G. (2005) · Clinical Science · doi:10.1042/cs20040329 · Cited by 117
Regulation of androgen receptor levels: Implications for prostate cancer progression and therapy
Burnstein, K. L. (2005) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20460 · Cited by 117
Cellular prostatic acid phosphatase: a protein tyrosine phosphatase involved in androgen-independent proliferation of prostate cancer
Veeramani, S., Yuan, T., Chen, S.-J., Lin, F., Petersen, J. E., Shaheduzzaman, S., Srivastava, S. K., MacDonald, R. G., & Lin, M. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00950 · Cited by 112
Site-specific Androgen Receptor Serine Phosphorylation Linked to Epidermal Growth Factor-dependent Growth of Castration-recurrent Prostate Cancer
Ponguta, L. A., Gregory, C. W., French, F. S., & Wilson, E. M. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m802392200 · Cited by 112
Integration of rapid signaling events with steroid hormone receptor action in breast and prostate cancer.
Lange, C., Gioeli, D., Hammes, S., & Marker, P. C. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.031905.160319 · Cited by 122
Regulation of Androgen Receptor and Prostate Cancer Growth by Cyclin-dependent Kinase 5
Hsu, F.-N., Chen, M. C., Chiang, M.-C., Lin, E., Lee, Y.-T., Huang, P.-H., Lee, G.-S., & Lin, H. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.252080 · Cited by 108
Efficacy and Safety of Single-Agent Pertuzumab (rhuMAb 2C4), a Human Epidermal Growth Factor Receptor Dimerization Inhibitor, in Castration-Resistant Prostate Cancer After Progression From Taxane-Based Therapy
Agus, D. B., Sweeney, C. J., Morris, M. J., Mendelson, D. S., McNeel, D. G., Ahmann, F. R., Wang, J., Derynck, M. K., Ng, K., Lyons, B., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.0649 · Cited by 107
Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases.
Liu, Y., Karaca, M., Zhang, Z., Gioeli, D., Earp, H. S., & Whang, Y. E. (2010) · Oncogene · doi:10.1038/onc.2010.103 · Cited by 106
Persistent androgen receptor-mediated transcription in castration-resistant prostate cancer under androgen-deprived conditions
Decker, K. F., Zheng, D., He, Y., Bowman, T. A., Edwards, J. R., & Li, J. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks888 · Cited by 106
Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer
Kallifatidis, G., Hoy, J. J., & Lokeshwar, B. L. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2016.06.003 · Cited by 110
Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets
Fontana, F., Raimondi, M., Marzagalli, M., Domizio, A. D., & Limonta, P. (2020) · Cells · doi:10.3390/cells9020460 · Cited by 111
Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells
Zheng, Y., Izumi, K., Yao, J. L., & Miyamoto, H. (2011) · Endocrine Related Cancer · doi:10.1530/erc-11-0010 · Cited by 104
Non-competitive androgen receptor inhibition in vitro and in vivo
Jones, J. O., Bolton, E. C., Huang, Y., Féau, C., Guy, R. K., Yamamoto, K. R., Hann, B. C., & Diamond, M. I. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807282106 · Cited by 104
Downregulation of androgen receptor expression by luteolin causes inhibition of cell proliferation and induction of apoptosis in human prostate cancer cells and xenografts
Chiu, F., & Lin, J. (2007) · The Prostate · doi:10.1002/pros.20690 · Cited by 103
Androgen receptor is frequently expressed in HER2-positive, ER/PR-negative breast cancers
Micello, D., Marando, A., Sahnane, N., Riva, C., Capella, C., & Sessa, F. (2010) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-010-0964-y · Cited by 102
Androgen axis in prostate cancer.
Culig, Z., & Bartsch, G. (2006) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20898 · Cited by 102
Inhibition of HER-2/neu Kinase Impairs Androgen Receptor Recruitment to the Androgen Responsive Enhancer
Liu, Y., Majumder, S., McCall, W., Sartor, C. I., Mohler, J. L., Gregory, C. W., Earp, H. S., & Whang, Y. E. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4292 · Cited by 99
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells
Zhang, Y., Wang, X. W., Jelovac, D., Nakanishi, T., Yu, M.-H., Akinmade, D., Goloubeva, O. G., Ross, D. D., Brodie, A. M. H., & Hamburger, A. W. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503829102 · Cited by 97
Androgen receptor (AR) expression in 400 breast carcinomas: is routine AR assessment justified?
Safarpour, D., Pakneshan, S., & Tavassoli, F. A. (2014) · Europe PMC (PubMed Central) · Cited by 97
Expression of androgen receptor splice variants in clinical breast cancers
Hickey, T. E., Irvine, C. M., Dvinge, H., Tarulli, G. A., Hanson, A. R., Ryan, N. K., Pickering, M. A., Birrell, S. N., Hu, D. G., Mackenzie, P. I., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6296 · Cited by 99
Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824
Chen, L., Meng, S., Wang, H., Bali, P., Bai, W., Li, B., Atadja, P. W., Bhalla, K. N., & Wu, J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0287 · Cited by 96
Frontier of Epilepsy Research - mTOR signaling pathway
Cho, C. (2011) · Experimental & Molecular Medicine · doi:10.3858/emm.2011.43.5.032 · Cited by 93
The status and role of ErbB receptors in human cancer
Überall, I., Kolář, Z., Trojanec, R., Berkovcová, J., & Hajdúch, M. (2008) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2007.12.002 · Cited by 92
A Road Map to Comprehensive Androgen Receptor Axis Targeting for Castration-Resistant Prostate Cancer
Mitsiades, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4414 · Cited by 91
Mechanisms of Androgen Receptor Activation in Castration-Resistant Prostate Cancer
Sharifi, N. (2013) · Endocrinology · doi:10.1210/en.2013-1466 · Cited by 96
A phase II study of lapatinib, a dual EGFR and HER-2 tyrosine kinase inhibitor, in patients with castration-resistant prostate cancer
Whang, Y. E., Armstrong, A. J., Rathmell, W. K., Godley, P. A., Kim, W. Y., Pruthi, R. S., Wallen, E., Crane, J. M., Moore, D. T., Grigson, G., et al. (2011) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2010.09.018 · Cited by 89
β4 Integrin signaling induces expansion of prostate tumor progenitors
Yoshioka, T., Otero, J. A., Chen, Y., Kim, Y. M., Koutcher, J. A., Satagopan, J. M., Reuter, V., Carver, B. S., de Stanchina, E., Enomoto, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci60720 · Cited by 88
Phase II Study of Androgen Synthesis Inhibition with Ketoconazole, Hydrocortisone, and Dutasteride in Asymptomatic Castration-Resistant Prostate Cancer
Taplin, M., Regan, M. M., Ko, Y., Bubley, G. J., Duggan, S., Werner, L. L., Beer, T. M., Ryan, C. W., Mathew, P. F., Tu, S., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1722 · Cited by 83
Molecular biology of prostate-cancer pathogenesis
Shand, R. L., & Gelmann, E. P. (2006) · Current Opinion in Urology · doi:10.1097/01.mou.0000193384.39351.64 · Cited by 84
Targeting ErbB3: the New RTK(id) on the Prostate Cancer Block
Jathal, M. K., Chen, L., Mudryj, M. M., & Ghosh, P. (2011) · Immunology Endocrine & Metabolic Agents - Medicinal Chemistry · doi:10.2174/187152211795495643 · Cited by 80
Transcriptional network of androgen receptor in prostate cancer progression
Takayama, K., & Inoue, S. (2013) · International Journal of Urology · doi:10.1111/iju.12146 · Cited by 83
Phosphoinositide 3-OH kinase p85α and p110β are essential for androgen receptor transactivation and tumor progression in prostate cancers
Zhu, Q., Youn, H., Tang, J., Tawfik, O. W., Dennis, K. L., Terranova, P. F., Du, J., Raynal, P., Thrasher, J. B., & Li, B. (2008) · Oncogene · doi:10.1038/onc.2008.91 · Cited by 80
Androgen-Dependent Regulation of Her-2/neu in Prostate Cancer Cells
Berger, R., Lin, D. I., Nieto, M., Sicińska, E., Garraway, L. A., Adams, H., Signoretti, S., Hahn, W. C., & Loda, M. F. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3928 · Cited by 79
Minireview: The Molecular and Genomic Basis for Prostate Cancer Health Disparities
Powell, I. J., & Bollig-Fischer, A. B. (2013) · Molecular Endocrinology · doi:10.1210/me.2013-1039 · Cited by 76
Mesenchymal and stem-like prostate cancer linked to therapy-induced lineage plasticity and metastasis
Han, H. H., Wang, Y., Curto, J., Gurrapu, S., Laudato, S., Rumandla, A., Chakraborty, G., Wang, X., Chen, H., Jiang, Y., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2022.110595 · Cited by 74
The novel role of pyrvinium in cancer therapy
Momtazi‐borojeni, A. A., Abdollahi, E., Ghasemi, F., Caraglia, M., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.26006 · Cited by 75
Androgen Receptor Remains Critical for Cell-Cycle Progression in Androgen-Independent CWR22 Prostate Cancer Cells
Yuan, X., Li, T., Wang, H., Zhang, T., Barua, M., Borgesi, R. A., Bubley, G. J., Lu, M. L., & Balk, S. P. (2006) · American Journal Of Pathology · doi:10.2353/ajpath.2006.051047 · Cited by 75
Improving the outcome of patients with castration-resistant prostate cancer through rational drug development
Attard, G., Sarker, D., Reid, A. H. M., Molife, R., Parker, C. C., & Bono, J. S. D. (2006) · British Journal of Cancer · doi:10.1038/sj.bjc.6603223 · Cited by 74
Kinases and protein phosphorylation as regulators of steroid hormone action
Weigel, N. L., & Moore, N. L. (2007) · Nuclear Receptor Signaling · doi:10.1621/nrs.05005 · Cited by 72
Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer
Perner, S., Cronauer, M. V., Schrader, A. J., Klocker, H., Čulig, Z., & Baniahmad, A. (2015) · Oncotarget · doi:10.18632/oncotarget.4689 · Cited by 71
Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations
Banneau, G., Guedj, M., MacGrogan, G. M., de Mascarel, I., Velasco, V., Schiappa, R., Bonadona, V., David, A., Dugast, C., Gilbert‐Dussardier, B., et al. (2010) · Breast Cancer Research · doi:10.1186/bcr2626 · Cited by 72
Evolving standards in the treatment of docetaxel-refractory castration-resistant prostate cancer
Antonarakis, E. S., & Armstrong, A. J. (2011) · Prostate Cancer and Prostatic Diseases · doi:10.1038/pcan.2011.23 · Cited by 74
Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer
Antonarakis, E. S., & Boudadi, K. (2016) · Clinical Medicine Insights Oncology · doi:10.4137/cmo.s34534 · Cited by 101

Authors: Mellinghoff, I. K., Vivanco, I., Kwon, A., Tran, C., Wongvipat, J., & Sawyers, C. L.
Affiliations: University of California, Los Angeles (US)
Howard Hughes Medical Institute (US)
Corresponding author: Sawyers, Charles L.
ORCID: Mellinghoff, Ingo K.
Vivanco, Igor
Sawyers, Charles L.
Venue: Cancer Cell
Publisher: Elsevier BV
Published: 2004-11
Volume: 6
Issue: 5
Pages: 517-527
ISSN: 1535-6108 (ISSN-L)
DOI: 10.1016/j.ccr.2004.09.031
OpenAlex: W2077863736
Cited by: 344
References: 80
Citations by year: 2026: 2 · 2025: 3 · 2024: 6 · 2023: 15 · 2022: 6 · 2021: 10 · 2020: 10 · 2019: 6 · 2018: 10 · 2017: 15 · 2016: 16 · 2015: 17 · 2014: 17 · 2013: 20 · 2012: 23
FWCI: 19.11
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (vor, 3180 d)
Locations: Cancer Cell (publishedVersion)
PubMed (publishedVersion)
Topics: Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
Keywords: HER2/neu, androgen receptor, HER3, prostate cancer, castration-resistant prostate cancer, protein stability, DNA binding, transcriptional activity, Akt-independent signaling, tyrosine kinase inhibitors
MeSH terms: Animals, Chlorocebus aethiops, DNA, Neoplasm, Humans, Male, Prostatic Neoplasms, Proto-Oncogene Proteins, Pyrimidines, Pyrroles, Receptors, Androgen, Transfection, Tumor Cells, Cultured, Signal Transduction, Protein Serine-Threonine Kinases, Receptor, ErbB-2, Erb-b2 Receptor Tyrosine Kinases, COS Cells, RNA, Small Interfering, Proto-Oncogene Proteins c-akt, ErbB Receptors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

HER2/neu kinase-dependent modulation of androgen receptor function through effects on DNA binding and stability.

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks